Clinical evidence summaries for type 2 diabetes, including glycaemic therapies, cardiovascular outcomes, kidney protection, complications, technology, obesity, and long-term safety.
A small crossover trial found almond milk offered no postprandial glycaemic benefit over 2% cow milk in adults with type 2 diabetes, with the primary glucose endpoint null. PICO summary and expert commentary.
A 52-week trial finds semaglutide shifts lipoprotein subfractions toward a less atherogenic profile in type 2 diabetes, independent of weight or glucose change. PICO summary and commentary.
A single-centre randomised controlled trial testing multidisciplinary multifactorial care against standard care in 192 adults with type 2 diabetes, with a modest HbA1c reduction and improved eGFR. PICO summary and expert commentary.
A phase IV randomized trial in 90 adults with type 2 diabetes found dapagliflozin plus exenatide augmented beta-cell function and insulin sensitivity above either agent alone, on surrogate OGTT measures. PICO summary and expert commentary.
A crossover trial finds orange juice with breakfast raises glucose no more than whole orange or a sugary drink of matched sugar in well-controlled type 2 diabetes. PICO summary and commentary.
An ACCORD analysis finds a triglyceride-glucose-waist index independently predicts cardiovascular events and mortality in type 2 diabetes, beating TyG alone. PICO summary and commentary.
A four-arm community trial finds integrated diabetes-and-periodontitis self-management improves glycaemic control and oral health more than single-disease care. PICO summary and commentary.
A controlled study finds adding vildagliptin to premixed insulin reduces glycaemic variability and improves time in range in type 2 diabetes. PICO summary and commentary.
A randomised trial finds dapagliflozin reduces myocardial fibrosis and improves cardiac structure in diabetic HFpEF. PICO summary and expert commentary.
An EXSCEL mediation analysis finds conventional risk-factor changes explain only part of exenatide's cardiovascular benefit and do not mediate its mortality effect. PICO summary and commentary.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
